Table 1.
Demographic Characteristics of the Patients with Prostate Cancer.*
| Characteristic | Case Series 1 (N = 150) |
Case Series 2 (N = 84) |
Case Series 3 (N = 131) |
Case Series 4 (N = 91) |
Case Series 5 (N = 69) |
Case Series 6 (N = 43) |
Case Series 7 (N = 124) |
All Case Series (N = 692) |
TCGA Cohort with Primary Prostate Cancer (N = 499)† |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| L-I Risk | High Risk | |||||||||||||||||||
| M | NM | M | NM | M | NM | M | NM | M | NM | M | NM | M | NM | M | NM | M | NM | M | NM | |
| number of patients | ||||||||||||||||||||
| Total | 15 | 135 | 9 | 75 | 16 | 115 | 8 | 83 | 7 | 62 | 4 | 39 | 23 | 101 | 82 | 610 | 4 | 158 | 19 | 318 |
| Age | ||||||||||||||||||||
| <50 yr | 2 | 16 | 0 | 2 | 1 | 6 | 1 | 5 | 1 | 2 | 0 | 3 | 2 | 9 | 7 | 43 | 0 | 15 | 1 | 11 |
| 50–59 yr | 6 | 40 | 4 | 30 | 3 | 37 | 2 | 18 | 2 | 15 | 0 | 6 | 9 | 47 | 26 | 193 | 3 | 63 | 8 | 103 |
| 60–69 yr | 6 | 63 | 3 | 24 | 11 | 56 | 3 | 38 | 3 | 20 | 2 | 25 | 11 | 36 | 39 | 262 | 1 | 67 | 8 | 167 |
| 70–79 yr | 1 | 15 | 1 | 11 | 1 | 15 | 2 | 19 | 1 | 11 | 2 | 5 | 1 | 9 | 9 | 85 | 0 | 13 | 2 | 37 |
| ≥80 yr | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 13 | 0 | 0 | 0 | 0 |
| Unknown | 0 | 0 | 1 | 6 | 0 | 0 | 0 | 2 | 0 | 6 | 0 | 0 | 0 | 0 | 1 | 14 | 0 | 0 | 0 | 0 |
| Race or ethnic background‡ | ||||||||||||||||||||
| Non-Hispanic white | 12 | 116 | 8 | 60 | 16 | 103 | 5 | 70 | 3 | 37 | 4 | 30 | 22 | 90 | 70 | 506 | 2 | 118 | 16 | 270 |
| Hispanic | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 7 | 0 | 0 | 0 | 0 | 3 | 8 | 0 | 1 | 1 | 5 |
| Non-Hispanic black | 1 | 8 | 0 | 4 | 0 | 12 | 2 | 0 | 1 | 5 | 0 | 2 | 0 | 5 | 4 | 36 | 2 | 27 | 2 | 27 |
| Asian or Pacific Islander | 1 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 1 | 0 | 1 | 1 | 11 | 0 | 3 | 0 | 9 |
| Other or unknown | 1 | 8 | 0 | 9 | 0 | 0 | 1 | 13 | 1 | 8 | 0 | 6 | 1 | 5 | 4 | 49 | 0 | 9 | 0 | 7 |
| History of cancer in a first- degree relative |
||||||||||||||||||||
| Prostate cancer | 4 | 31 | 3 | 11 | 2 | 16 | 0 | 14 | 2 | 12 | 0 | 4 | 5 | 29 | 16 | 117 | NA | NA | NA | NA |
| Other cancer | 10 | 55 | 4 | 35 | 8 | 53 | 6 | 30 | 3 | 14 | 1 | 19 | 19 | 64 | 51 | 270 | NA | NA | NA | NA |
| No cancer | 2 | 46 | 2 | 27 | 5 | 35 | 1 | 25 | 3 | 29 | 1 | 12 | 4 | 25 | 18 | 199 | NA | NA | NA | NA |
| Unknown | 2 | 15 | 1 | 5 | 2 | 17 | 1 | 21 | 1 | 9 | 2 | 6 | 0 | 0 | 9 | 73 | NA | NA | NA | NA |
| Gleason score§ | ||||||||||||||||||||
| ≤6 | 0 | 8 | 0 | 3 | 0 | 11 | 1 | 9 | 1 | 3 | 0 | 2 | 0 | 4 | 2 | 40 | 1 | 32 | 1 | 11 |
| 3+4 | 0 | 19 | 1 | 9 | 0 | 10 | 1 | 6 | 1 | 3 | 0 | 2 | 2 | 11 | 5 | 60 | 3 | 94 | 1 | 50 |
| 4+3 | 1 | 18 | 2 | 7 | 1 | 11 | 0 | 15 | 2 | 7 | 0 | 4 | 4 | 20 | 10 | 82 | 0 | 32 | 5 | 64 |
| 8–10 | 11 | 70 | 3 | 44 | 12 | 65 | 6 | 39 | 3 | 28 | 4 | 16 | 17 | 64 | 56 | 326 | 0 | 0 | 12 | 193 |
| Unknown | 3 | 20 | 3 | 12 | 3 | 18 | 0 | 14 | 0 | 21 | 0 | 15 | 0 | 2 | 9 | 102 | 0 | 0 | 0 | 0 |
The studies included in each case series were as follows: 1, Stand Up To Cancer–Prostate Cancer Foundation discovery series; 2, Stand Up To Cancer–Prostate Cancer Foundation validation series; 3, Royal Marsden Hospital; 4, University of Washington; 5, Weill Cornell Medical College; 6, University of Michigan; and 7, Memorial Sloan Kettering Cancer Center. L-I denotes low to intermediate, M mutation present, NA not applicable, and NM no mutation present.
The Cancer Genome Atlas (TCGA) cohort includes a series of patients with localized prostate cancer.
Race and ethnic background were self-reported.
The Gleason score is a measure of the differentiation state of prostate cancer; scores range from 2 to 10, with higher scores associated with worse clinical outcomes. When two grades are given (e.g., 3+4), the first indicates the more common grade found in the tumor.